Lee:Literature Proteasomes

Home        Research        Lab Members        Publications        Transporters        Proteasomes        PK/PD/PGx        JC        Links        Internal        Contact       

Feel free to add articles ...

Proteasome Biology general review

1. Hoeller D and Dikic I. Targeting the ubiquitin system in cancer therapy. Nature. 2009 Mar 26;458(7237):438-44. DOI:10.1038/nature07960 |
2. Mani A and Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol. 2005 Jul 20;23(21):4776-89. DOI:10.1200/JCO.2005.05.081 |
3. Murata S, Yashiroda H, and Tanaka K. Molecular mechanisms of proteasome assembly. Nat Rev Mol Cell Biol. 2009 Feb;10(2):104-15. DOI:10.1038/nrm2630 |

Immunoproteasome

1. Fitzpatrick LR, Small JS, Poritz LS, McKenna KJ, and Koltun WA. Enhanced intestinal expression of the proteasome subunit low molecular mass polypeptide 2 in patients with inflammatory bowel disease. Dis Colon Rectum. 2007 Mar;50(3):337-48; discussion 348-50. DOI:10.1007/s10350-006-0796-7 |
2. Gavilán MP, Castaño A, Torres M, Portavella M, Caballero C, Jiménez S, García-Martínez A, Parrado J, Vitorica J, and Ruano D. Age-related increase in the immunoproteasome content in rat hippocampus: molecular and functional aspects. J Neurochem. 2009 Jan;108(1):260-72. DOI:10.1111/j.1471-4159.2008.05762.x |
3. Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, and Orlowski RZ. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood. 2009 May 7;113(19):4667-76. DOI:10.1182/blood-2008-07-171637 |
4. Ho YK, Bargagna-Mohan P, Wehenkel M, Mohan R, and Kim KB. LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem Biol. 2007 Apr;14(4):419-30. DOI:10.1016/j.chembiol.2007.03.008 |
5. Heink S, Fricke B, Ludwig D, Kloetzel PM, and Krüger E. Tumor cell lines expressing the proteasome subunit isoform LMP7E1 exhibit immunoproteasome deficiency. Cancer Res. 2006 Jan 15;66(2):649-52. DOI:10.1158/0008-5472.CAN-05-2872 |
6. Namiki S, Nakamura T, Oshima S, Yamazaki M, Sekine Y, Tsuchiya K, Okamoto R, Kanai T, and Watanabe M. IRF-1 mediates upregulation of LMP7 by IFN-gamma and concerted expression of immunosubunits of the proteasome. FEBS Lett. 2005 May 23;579(13):2781-7. DOI:10.1016/j.febslet.2005.04.012 |
7. Mishto M, Bellavista E, Santoro A, Stolzing A, Ligorio C, Nacmias B, Spazzafumo L, Chiappelli M, Licastro F, Sorbi S, Pession A, Ohm T, Grune T, and Franceschi C. Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiol Aging. 2006 Jan;27(1):54-66. DOI:10.1016/j.neurobiolaging.2004.12.004 |
8. Mishto M, Luciani F, Holzhütter HG, Bellavista E, Santoro A, Textoris-Taube K, Franceschi C, Kloetzel PM, and Zaikin A. Modeling the in vitro 20S proteasome activity: the effect of PA28-alphabeta and of the sequence and length of polypeptides on the degradation kinetics. J Mol Biol. 2008 Apr 11;377(5):1607-17. DOI:10.1016/j.jmb.2008.01.086 |
9. Mishto M, Bonafè M, Salvioli S, Olivieri F, and Franceschi C. Age dependent impact of LMP polymorphisms on TNFalpha-induced apoptosis in human peripheral blood mononuclear cells. Exp Gerontol. 2002 Jan-Mar;37(2-3):301-8. DOI:10.1016/s0531-5565(01)00196-6 |
10. Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer F, Störkel S, and Seliger B. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer. 2004 Mar 20;109(2):265-73. DOI:10.1002/ijc.11681 |
11. Visekruna A, Joeris T, Schmidt N, Lawrenz M, Ritz JP, Buhr HJ, and Steinhoff U. Comparative expression analysis and characterization of 20S proteasomes in human intestinal tissues: The proteasome pattern as diagnostic tool for IBD patients. Inflamm Bowel Dis. 2009 Apr;15(4):526-33. DOI:10.1002/ibd.20805 |